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Abstract.  We  report  pharmacokinetic  data  on  two  gastrectomized,  patients  affected  by
tuberculosis. Drugs plasmatic concentrations were measured after seven days of oral therapy by a 
validated high performance liquid chromatography
the area under the concentration-
therapeutic level of isoniazid was found in a patient with total gastrectomy 
mg\L and AUC0-24 level of 4.75 hr*mg/L. The level of the o
These findings support the need to monitor anti tubercular drug levels to facilitate early detection 
of therapeutic failure, above all in patients treated with isoniazid and with potential problems on 
oral drugs absorption.
Introduction.  Little  is  known  of  antitubercular 
treatment in gastrectomized patients. By
search we found no evidence in the literature regarding 
the antitubercular drugs absorption after gastrectomy. 
Total and partial gastric resection alters the anatomy 
and  secretory  activity  of  the  gastrointestinal  tract.  It 
might  be  expected  that  the  consequences  of  such 
changes should affect the pharmacokinetics, e
concerning the absorption of orally administered drugs 
that  are  primarily  absorbed  in  the  stomach  or 
duodenum leading to sub-therapeutic drugs level. 
Case Studies and Methods. We report here the case of 
two  consecutive  gastrectomized  patients  a
; Open Journal System 
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We  report  pharmacokinetic  data  on  two  gastrectomized,  patients  affected  by
Drugs plasmatic concentrations were measured after seven days of oral therapy by a 
validated high performance liquid chromatography-mass spectrometry (HPLC
-time-curve (AUC) over 24 hours (AUC0-24
therapeutic level of isoniazid was found in a patient with total gastrectomy 
hr*mg/L. The level of the other antitubercular drugs was adequate. 
These findings support the need to monitor anti tubercular drug levels to facilitate early detection 
of therapeutic failure, above all in patients treated with isoniazid and with potential problems on 
Little  is  known  of  antitubercular 
By a MEDLINE 
search we found no evidence in the literature regarding 
antitubercular drugs absorption after gastrectomy. 
Total and partial gastric resection alters the anatomy 
and  secretory  activity  of  the  gastrointestinal  tract.  It 
might  be  expected  that  the  consequences  of  such 
changes should affect the pharmacokinetics, especially 
concerning the absorption of orally administered drugs 
that  are  primarily  absorbed  in  the  stomach  or 
therapeutic drugs level. 
We report here the case of 
two  consecutive  gastrectomized  patients  affected  by 
tuberculosis.  To  estimate  the  degree  to  which 
absorption is impaired, the drug levels were measured 
in duplicate plasma samples. The patients were fasting 
at the time of drugs intake. Plasma sample levels were 
measured  by  a  validated  high  perfor
chromatography-mass  spectrometry  (HPLC
method with the following lower limit of quantification 
(LOQ) and detection (LOD): 0.015 mg/L (LOQ) and 
0.007 mg/L (LOD) for isoniazid; 0.195 mg/L (LOQ) 
and 0.048 mg/L (LOD) for pyrazinamide; 0.019 mg
(LOQ)  and  0.008  mg/L  (LOD)  for  rifampin;  0.020 
mg/L (LOQ) and 0.010 mg/L (LOD) for ethambutol.
Non-compartmental  pharmacokinetic  analysis  of  the 
data  was  performed  using  Kinetica  version  5.0 
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We  report  pharmacokinetic  data  on  two  gastrectomized,  patients  affected  by
Drugs plasmatic concentrations were measured after seven days of oral therapy by a 
mass spectrometry (HPLC-MS) method and 
24) was calculated. A sub-
therapeutic level of isoniazid was found in a patient with total gastrectomy with a Cmax of 0,395 
ther antitubercular drugs was adequate. 
These findings support the need to monitor anti tubercular drug levels to facilitate early detection 
of therapeutic failure, above all in patients treated with isoniazid and with potential problems on 
tuberculosis.  To  estimate  the  degree  to  which 
absorption is impaired, the drug levels were measured 
in duplicate plasma samples. The patients were fasting 
at the time of drugs intake. Plasma sample levels were 
measured  by  a  validated  high  performance  liquid 
mass  spectrometry  (HPLC-MS) 
method with the following lower limit of quantification 
(LOQ) and detection (LOD): 0.015 mg/L (LOQ) and 
0.007 mg/L (LOD) for isoniazid; 0.195 mg/L (LOQ) 
and 0.048 mg/L (LOD) for pyrazinamide; 0.019 mg/L 
(LOQ)  and  0.008  mg/L  (LOD)  for  rifampin;  0.020 
mg/L (LOQ) and 0.010 mg/L (LOD) for ethambutol.
compartmental  pharmacokinetic  analysis  of  the 
data  was  performed  using  Kinetica  version  5.0 Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
software  (Thermo  Fisher  Scientific).  The  area  under 
the  concentration-time  curve  (AUC)  over  24  hours 
(AUC0-24) in plasma was calculated by the linear-log 
trapezoidal  rule,  using  the  same  Ctrough concentration 
for  time  0  and  24  and  applying  a  limited  sampling 
model.
1
Case 1. A 68-year-old, HIV negative was affected 
by tubercular (TB) epididymitis. His previous medical 
history  was  remarkable  for  a  total  gastrectomy with 
Roux-en-Y  gastric  bypass  procedure  performed  five 
years before, due to gastric cancer. His renal and liver 
function was normal. His weight was 65Kg. He was 
treated  with  standard  oral  anti  TB  therapy including 
isoniazid  300  mg  daily,  rifampin  600  mg  daily, 
ethambutol 1200 mg daily and pyrazinamide 2000 mg 
daily,  vitamin  B6  300  mg  daily.  His  chronic 
medications were: enalapril 20 mg daily, amlodipine 5 
mg daily, ticlopidine 500 mg daily. Therefore plasma 
concentrations of anti TB drugs were measured after 
seven  days  of  drug  intake  in  the  hospital.  Plasma 
samples  were  collected  before  the  drug  intake  to 
measure Ctrough and after 2 hours to measure Cmax (peak 
plasma concentration). We found  very low  Cmax and 
AUC0-24 levels  of  isoniazid  (0,395  mg\L  and  4.75 
hr*mg/L  respectively),  not  attributable  to  patient’s 
anti-hypertensive  and  anti-tubercular  drug-drug 
interaction.  The  results  of  plasma  concentrations,
AUC0-24 and the therapeutic expected range are shown 
in  the  following  table.  The  patient  obtained  slow 
clinical improvement. 
Case  2. A  65-year-old  HIV  negative woman  was 
affected by pulmonary tuberculosis. She underwent a 
partial gastrectomy for a gastric ulcer 15 years earlier. 
Her weight was 39 Kg; she was treated with standard 
anti  TB  therapy  including  isoniazid  250  mg  daily, 
rifampin 600 mg daily, ethambutol 1000 mg daily and 
pyrazinamide 1000 mg daily, vitamin B6 300 mg daily. 
The drugs were administered intra venous (iv) in the 
first 15 days and oral subsequently (pyrazinamide and 
vitamin B6 were always administered orally). No other 
drugs  were  taken  by  this  patient. We  studied  the 
plasmatic drugs concentration in the course of iv and 
oral therapy. Plasma samples were collected before the 
daily drug intake to measure Ctrough and after 2 hours 
and  5  hours  to  measure Cmax.  The  results  of  plasma 
concentrations, AUC0-24 during oral therapy are shown 
in the table. During iv therapy the measured AUC0-24
was very similar from the one reported in the course of 
oral  treatment:  isoniazid  26.70  hr*mg/L,  rifampin 
154.87 hr*mg/L,  ethambutol  32.48 hr*mg/L.  The 
patient obtained adequate clinical response.
Discussion. To our knowledge, data regarding the first 
line antitubercular drugs absorption after gastrectomy 
are  scantily.  Overall  the  measured  plasmatic 
antitubercular  drugs  in  gastrectomized  patients  were 
generally  adequate. We  observed  that  a  patient 
undergoing a complete gastric resection followed by a 
Roux-en-Y gastric bypass procedure (case 1) had poor 
isoniazid plasmatic level. In the second case with the 
patient who had undergone a partial gastric resection, 
the absorption of isoniazid was right and comparable to 
iv  administration.  Rifampin,  ethambutol  and 
pyrazinamide  in  both  patients  always  had  suitable 
level.
Obviously,  a  single  case  study  has  several 
limitations principally linked to individual variability, 
thus we can’t draw conclusions. In addition, in case 1
we  have  calculated  the  AUC0-24 from  two 
determinations  only  according  to  a  validated  limited
Table 1. Anti-tubercular drugs plasma concentration and therapeutic range references.
Anti 
tubercular 
drugs 
Time 
after 
dose, h
Patient 
1 Patient 1
Patient 1 
AUC0-24
(hr*mg/L)
Patient 
2 Patient 2
Patient 2 
AUC0-24
(hr*mg/L)
Expected therapeutic 
references mg/L
Expected 
range of 
AUC0-24
(hr*mg/L)
(Cmax, 
Ctrough)
dose 
mg/day
Drug plasma 
concentration 
mg/L
dose 
mg/day
Drug plasma 
concentration 
mg/L
(Cmax and Cut-off 
Cmax)
Isoniazid  
2
300 
(4.6)*
0.395
4.75 250 
(6.4)*
5.05
37.61 Cmax 9-15[5] Cut-off 
Cmax 3.0 [5]
10.52 -
111.80 
[8,9]
5 ND 2.2
24 < 0.007 (LOD) 0.03
Rifampin 
2
600 
(9.2)*
9.671
116.40  600 
(15)*
12.67
145.37 Cmax 9.65- 24.99 [6] 
Cut-off Cmax 8.0 [7]
47.40.-
142.73 [6] 5 ND 9.64
24 0.029 0.72
ethambutol  
2
1200 
(18.5)*
4.547
54.58 1000 
(25)*
7.08
57.43 Cut-off Cmax 2.0 [6] ND 5 ND 2.94
24 < 0.010 (LOD) 0.70
pyrazinamide 
2
2000 
(30.7)*
47.269
5832.50 1000 
(25)*
32.53
337.22 Cmax 21.70- 42.64 [6] 
Cut-off Cmax 35.0 [7]
303.35-
541.36 [6] 5 ND 21.54
24 13.346 1.84
Area under the concentration-time curve (AUC0-24); lower limit of detection (LOD); *mg per Kg per day; ND=unavailable.Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
sampling model,
1 and assuming Cmax appropriate after 
two  hours  of  drugs  intake. Even  considering  these 
limitations, we believe the observation is important at 
least  for  two  reasons:  firstly,  it  is  known  that 
gastrectomy  patients  have  greater  risk  of  having 
tuberculosis  in  later  life  and  preventive  therapy  is 
mainly based on isoniazid administration;
2,3 secondly, 
low serum concentration of antitubercular drugs have 
been associated with treatment failure, relapse and drug 
resistance.
4
Although  the  clinical  significance  of  low 
concentration should be defined, it may be necessary to 
optimise drug dosages by TDM, especially in patients 
with an inadequate clinical response. 
These  findings  support  the  need  to  monitor  anti 
tubercular  drug levels  to  facilitate  early detection  of 
therapeutic failure above all in patients with potential 
problems on oral drugs absorption.
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